Sale

Hyperphosphatemia Therapeutics Market

Global Hyperphosphatemia Therapeutics Market Share, Trends: By Product type: Sevelamer, Calcium-Based Phosphate Blinders, Iron-based Phosphate Binders, Aluminium-based Phosphate Blinders; By Form; By Distribution Channels; Regional Analysis; Competitive Landscape; Key Trends and Developments in the Market; 2024-2032

Global Hyperphosphatemia Therapeutics Market Outlook

The global hyperphosphatemia therapeutics market would likely grow at a CAGR of 5.4% during 2024-2032. Asia, North America and Europe are likely to be key markets. 

 

Global Market Likely to be Driven by Need for Effective Treatment for Hyperphosphatemia

Hyperphosphatemia refers to serum phosphate concentration > 4.5 mg/dL (> 1.46 mmol/L). Metabolic or respiratory acidosis, Chronic kidney disease, and hypoparathyroidism could be possible causes. Serum phosphate measurement is carried out for diagnosis. Treatment may comprise limited intake of phosphate and taking phosphate-binding antacids, like calcium carbonate.

 

hyperphosphatemia therapeutics market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Reduced renal excretion of phosphate may generally be a cause of hyperphosphatemia. Hyperphosphatemia irregularly caused by a large transcellular movement of phosphate into the extracellular space, overwhelming the renal excretory capacity. Such transcellular movement frequently takes place in diabetic ketoacidosis, nontraumatic rhabdomyolysis, crush injuries, overwhelming systemic infections, tumour lysis syndrome. Hyperphosphatemia may also take place due to excessive oral phosphate administration, and, at times, with overuse of enemas carrying phosphate.

 

Advancements in Drug Development Likely to Boost Market Growth

Advancements in research and treatment systems are expected to drive the global hyperphosphatemia therapeutics market. For example, in 2023, it was reported that Lupin had launched Sevelamer Hydrochloride tablets (800 mg) – a medicine employed to treat hyperphosphatemia in individuals suffering from chronic kidney disease – in USA. The product had been introduced after obtaining USFDA approval.

 

In 2021, it was reported that individuals with chronic kidney disease on maintenance dialysis felt enhanced control of hyperphosphatemia when a dual treatment comprising tenapanor and phosphate binders was administered as against the administration of only phosphate binders or only tenapanor.

 

In 2020, Unicycive Therapeutics acquired Renazorb (Lanthanum Dioxycarbonate) from Spectrum Pharmaceuticals for the treatment of hyperphosphatemia in individuals with chronic kidney disease. Renazorb has exhibited distinct phosphate binding features with the potential to treat hyperphosphatemia in chronic kidney disease patients with significant patient adherence advantages including smaller and lesser pills per dose than current care standards. Such developments are expected to boost the global hyperphosphatemia therapeutics market.

 

In 2020, Ardelyx, Inc. announced the submission of New Drug Application (NDA) for tenapanor to USFDA for regulation of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

 

hyperphosphatemia therapeutics market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Segmentation

By product type, the market is divided into:

  • Sevelamer
  • Calcium-Based Phosphate Blinders
  • Iron-based Phosphate Binders
  • Aluminium-based Phosphate Blinders
  • Others

 

By form, the market is classified into:

  • Capsules
  • Tablet
  • Syrup

 

On the basis of distribution channel, the market is segmented into:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online

 

By region, the market is classified into:

  • Europe
  • North America
  • Latin America
  • Asia Pacific
  • Middle East and Africa

 

hyperphosphatemia therapeutics market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Industry Players in the Market

The report offers an extensive assessment of major players in the global hyperphosphatemia therapeutics market; it evaluates their capability, observes latest occurrences such as mergers and acquisitions, capacity expansions, and plant turnarounds:

 

  • Astellas Pharma Inc.
  • Akebia Therapeutics, Inc
  • Lupin Limited
  • Ardelyx, Inc
  • Vifor Pharma Management Ltd.
  • Others

 

Using SWOT analysis and Porter’s Five Forces model, the EMR report offers deep insights into the industry.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product type
  • Form
  • Distribution Channels
  • Region
Breakup by Product type
  • Sevelamer
  • Calcium-Based Phosphate Blinders
  • Iron-based Phosphate Binders
  • Aluminium-based Phosphate Blinders
  • Others
Breakup by Form
  • Capsules
  • Tablet
  • Syrup
Breakup by Distribution Channels
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Astellas Pharma Inc.
  • Akebia Therapeutics, Inc
  • Lupin Limited
  • Ardelyx, Inc
  • Vifor Pharma Management Ltd.
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties 
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Hyperphosphatemia Therapeutics Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Hyperphosphatemia Therapeutics Historical Market (2017-2023) 
    8.3    Global Hyperphosphatemia Therapeutics Market Forecast (2024-2032)
    8.4    Global Hyperphosphatemia Therapeutics Market by Product type
        8.4.1    Sevelamer
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2023)
            8.4.1.3    Forecast Trend (2024-2032)
        8.4.2    Calcium-Based Phosphate Blinders
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2023)
            8.4.2.3    Forecast Trend (2024-2032)
        8.4.3    Iron-based Phosphate Binders
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2023)
            8.4.3.3    Forecast Trend (2024-2032)
        8.4.4    Aluminium-based Phosphate Blinders
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2017-2023)
            8.4.4.3    Forecast Trend (2024-2032)
        8.4.5    Others
    8.5    Global Hyperphosphatemia Therapeutics Market by Form
        8.5.1    Capsules
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2023)
            8.5.1.3    Forecast Trend (2024-2032)
        8.5.2    Tablet
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2023)
            8.5.2.3    Forecast Trend (2024-2032)
        8.5.3    Syrup
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2023)
            8.5.3.3    Forecast Trend (2024-2032)
    8.6    Global Hyperphosphatemia Therapeutics Market by Distribution Channels
        8.6.1    Hospital Pharmacies
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2023)
            8.6.1.3    Forecast Trend (2024-2032)
        8.6.2    Retail Pharmacies
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2023)
            8.6.2.3    Forecast Trend (2024-2032)
        8.6.3    Online
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2017-2023)
            8.6.3.3    Forecast Trend (2024-2032)
    8.7    Global Hyperphosphatemia Therapeutics Market by Region
        8.7.1    North America
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2017-2023) 
            8.7.1.3    Forecast Trend (2024-2032)
        8.7.2    Europe
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2017-2023) 
            8.7.2.3    Forecast Trend (2024-2032)
        8.7.3    Asia Pacific
            8.7.3.1    Market Share
            8.7.3.2    Historical Trend (2017-2023) 
            8.7.3.3    Forecast Trend (2024-2032)
        8.7.4    Latin America
            8.7.4.1    Market Share
            8.7.4.2    Historical Trend (2017-2023) 
            8.7.4.3    Forecast Trend (2024-2032)
        8.7.5    Middle East and Africa
            8.7.5.1    Market Share
            8.7.5.2    Historical Trend (2017-2023) 
            8.7.5.3    Forecast Trend (2024-2032)
9    North America Hyperphosphatemia Therapeutics Market Analysis
    9.1    United States of America 
        9.1.1    Market Share
        9.1.2    Historical Trend (2017-2023) 
        9.1.3    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Market Share
        9.2.2    Historical Trend (2017-2023) 
        9.2.3    Forecast Trend (2024-2032)
10    Europe Hyperphosphatemia Therapeutics Market Analysis
    10.1    United Kingdom
        10.1.1    Market Share
        10.1.2    Historical Trend (2017-2023) 
        10.1.3    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Market Share
        10.2.2    Historical Trend (2017-2023) 
        10.2.3    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Market Share
        10.3.2    Historical Trend (2017-2023) 
        10.3.3    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Market Share
        10.4.2    Historical Trend (2017-2023) 
        10.4.3    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Hyperphosphatemia Therapeutics Market Analysis
    11.1    China
        11.1.1    Market Share
        11.1.2    Historical Trend (2017-2023) 
        11.1.3    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Market Share
        11.2.2    Historical Trend (2017-2023) 
        11.2.3    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Market Share
        11.3.2    Historical Trend (2017-2023) 
        11.3.3    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Market Share
        11.4.2    Historical Trend (2017-2023) 
        11.4.3    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Market Share
        11.5.2    Historical Trend (2017-2023) 
        11.5.3    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Hyperphosphatemia Therapeutics Market Analysis
    12.1    Brazil
        12.1.1    Market Share
        12.1.2    Historical Trend (2017-2023) 
        12.1.3    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Market Share
        12.2.2    Historical Trend (2017-2023) 
        12.2.3    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Market Share
        12.3.2    Historical Trend (2017-2023) 
        12.3.3    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Hyperphosphatemia Therapeutics Market Analysis
    13.1    Saudi Arabia
        13.1.1    Market Share
        13.1.2    Historical Trend (2017-2023) 
        13.1.3    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Market Share
        13.2.2    Historical Trend (2017-2023) 
        13.2.3    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Market Share
        13.3.2    Historical Trend (2017-2023) 
        13.3.3    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Market Share
        13.4.2    Historical Trend (2017-2023) 
        13.4.3    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    Astellas Pharma Inc.
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    Akebia Therapeutics, Inc
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Lupin Limited
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    Ardelyx, Inc
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    Vifor Pharma Management Ltd.
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications
        15.2.6    Others
16    Key Trends and Developments in the Market

 

List of Figures and Tables

1.    Global Hyperphosphatemia Therapeutics Market: Key Industry Highlights, 2017 and 2032
2.    Global Hyperphosphatemia Therapeutics Historical Market: Breakup by Product Type (USD Million), 2017-2023
3.    Global Hyperphosphatemia Therapeutics Market Forecast: Breakup by Product Type (USD Million), 2024-2032
4.    Global Hyperphosphatemia Therapeutics Historical Market: Breakup by Distribution Channel (USD Million), 2017-2023
5.    Global Hyperphosphatemia Therapeutics Market Forecast: Breakup by Distribution Channel (USD Million), 2024-2032
6.    Global Hyperphosphatemia Therapeutics Historical Market: Breakup by Region (USD Million), 2017-2023
7.    Global Hyperphosphatemia Therapeutics Market Forecast: Breakup by Region (USD Million), 2024-2032
8.    North America Hyperphosphatemia Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2023
9.    North America Hyperphosphatemia Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
10.    Europe Hyperphosphatemia Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2023
11.    Europe Hyperphosphatemia Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
12.    Asia Pacific Hyperphosphatemia Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2023
13.    Asia Pacific Hyperphosphatemia Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Latin America Hyperphosphatemia Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2023
15.    Latin America Hyperphosphatemia Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Middle East and Africa Hyperphosphatemia Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2023
17.    Middle East and Africa Hyperphosphatemia Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
18.    Global Hyperphosphatemia Therapeutics Market Structure

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER